In vitro activity of linezolid against clinical isolates of Fusobacterium spp

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 4, 2006, Pages 789-793

  Daeschlein, G ^a   Hoehne, C ^a   Assadian, Ojan ^b   Daxboeck, F ^b   Meinl, C ^b   Kramer, A ^c   Kekule A S ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Amoxicillin; Amoxicillin clavulanic acid; Anaerobic bacteria; MIC; Resistance; Susceptibility

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; LINEZOLID;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; FUSOBACTERIUM; FUSOBACTERIUM MORTIFERUM; FUSOBACTERIUM NECROPHORUM; FUSOBACTERIUM NUCLEATUM; FUSOBACTERIUM VARIUM; GRAM NEGATIVE ANAEROBIC BACTERIA; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES DIFFERENCE;

ACETAMIDES; ANAEROBIOSIS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; FUSOBACTERIUM; HUMANS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; SPECIES SPECIFICITY;

EID: 33748695299     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl338     Document Type: Article

References (29)

1. Diekema D, Jones R. Oxazolidinones: A review. Drugs 2000; 59: 7-16.
2. Clemett D, Markham A. Linezolid. Drugs 2000; 59: 815-27.
3. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45: 797-802.
4. Fines M, Leclercq R. Influence of mechanisms of resistance to antibiotics that bind to the 50S ribosomal subunit on the activity of linezolid against Gram-positive organisms. In: Programs and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. C183, Paper 847. 118-8.
5. Perry CM, Jarvis B. Linezolid. A Review of its use in the management of serious Gram-positive infections. Drugs 2001; 61: 525-51.
6. Brauers J, Kresken M, Hafner D et al. Surveillance of linezolid resistance in Germany, 2001-2002. Clin Microbiol Infect 2005; 11: 39-46.
7. Zurenko GE, Yagi BH, Schaadt RD et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-45.
8. Yagi B, Zurenko G. In vitro activity of Linezolid and Eperezolid, two novel oxazolidinone antimicrobial agents, against anaerobic bacteria. Anaerobe 1997; 3: 301-6.
9. Edlund C, Oh H, Nord CE. In vitro activity of linezolid and eperezolid against anaerobic bacteria. Clin Microbiol Infect 1999; 5: 51-3.
10. Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother 1999; 43: 1469-74.
11. Ednie LM, Jacobs MR, Appelbaum PC. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents. J Antimicrob Chemother 2002; 50: 101-5.
12. Behra-Miellet J, Calvet L, Dubreuil L. Activity of linezolid against anaerobic bacteria. Int J Antimicrob Agents 2003; 22: 28-34.
13. Citron DM, Merriam CV, Tyrrell KL et al. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003; 47: 2334-8.
14. Phillips OA, Rotimi VO, Jamal WY et al. Comparative in vitro activity of PH-027 versus linezolid and other anti-anaerobic antimicrobials against clinical isolates of Clostridium difficile and other anaerobic bacteria. J Chemother 2003; 15: 113-7.
15. Holdeman LV, Moore WEC. Anaerobic Laboratory Manual, 4th edn. Blacksburg: Virginia Polytechnic Institute and State University, 1977.
16. Murray PR, Baron EJ, Pfaller MA et al. Manual of Clinical Microbiology, 6th edn. Washington DC: American Society for Microbiology, 1995.
17. Mutters R, Ihm P, Pohl S et al. Reclassification of the genus Pasteurella Trevisan 1887 on the basis of deoxyribonucleic acid homology, with proposals for the new species Pasteurella dagmatis, Pasteurella canis, Pasteurella stomatis, Pasteurella anatis, and Pasteurella langaa. Int J Syst Bacteriol 1985; 35: 309-22.
18. Jousimies-Somer HR, Summanen P, Citron DM et al. Wadsworth - KTL Anaerobic Bacteriology Manual, 6th edn. Belmont, CA: Star Publishing Co., 2002.
19. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Linezolid breakpoints. EUCAST definitive document E. Def. 4.1. Clin Microbiol Infect 2001; 7: 283-4.
20. Deutsche Industrie Norm (DIN). Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika - Teil 4: Bewertungsstufen für die minimale Hemmkonzentration; MHK-Grenzwerte von antimikrobiellen Wirkstoffen. DIN 58940-4 Bbl 1; 2004-02.
21. Brook I. Recovery of anaerobic bacteria from clinical specimens in 12 years at two military hospitals. J Clin Microbiol 1988; 26: 1181-8.
22. Gajardo M, Silva N, Gomez L et al. Prevalence of periodontopathic bacteria in aggressive periodontitis patients in a Chilean population. J Periodontol 2005; 76: 289-94.
23. Marina M, Strong CA, Civen R et al. Bacteriology of pleuropulmonary infections: Preliminary report. Clin Inf Dis 1993; 16 Suppl 4: 256-62.
24. Landsaat PM, van der Lelie H, Bongaerts G et al. Fusobacterium nucleatum, a new invasive pathogen in neutropenic patients? Scand J Infect Dis 1995; 27: 83-4.
25. Finegold SM, George WL. Anaerobic Infections in Humans. New York: Academic Press Inc., 1989; 793-818.
26. Epaulard O, Brion JP, Stahl JP et al. The changing pattern of fusobacterium infections in humans: Recent experience with fusobacterium bacteraemia. Clin Microbiol Infect 2006; 12: 178-81.
27. George WL, Kirby BD, Sutter VL et al. Gram-negative anaerobic bacilli: Their role in infection and patterns of susceptibility to antimicrobial agents. II. Little-known Fusobacterium species and miscellaneous genera. Rev Infect Dis 1981; 3: 599-626.
28. Aldridge KE, Ashcraft D, Cambre K et al. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001; 45: 1238-43.
29. van Winkelhoff AJ, Herrera D, Oteo A et al. Antimicrobial profiles of periodontal pathogens isolated from periodontitis patients in The Netherlands and Spain. J Clin Periodontol 2005; 32: 893-8.